Cronos Group Inc Overview
Industry: Drug Manufacturers Specialty & Generic
Sector: Healthcare
Cronos Group Inc. operates as a cannabinoid company. It manufactures, markets, and distributes hemp-derived supplements and cosmetic products through e-commerce, retail, and hospitality partner channels under the Lord Jones brand in the United States. The company is also involved in the cultivation, manufacture, and marketing of cannabis and cannabis-derived products for the medical and adult-use markets. It sells cannabis and cannabis products, including dried cannabis, pre-rolls, edibles, concentrates, and cannabis extracts through wholesale and direct-to-client channels under its wellness platform, PEACE NATURALS; and operates under adult-use brands, Spinach. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada. Cronos Group Inc. operates as a cannabinoid company. It manufactures, markets, and distributes hemp-derived supplements and cosmetic products through e-commerce, retail, and hospitality partner channels under the Lord Jones brand in the United States. The company is also involved in the cultivation, Read MoreMavefund brings filings, fundamentals, valuation, price history and news for Cronos Group Inc into one research view. The sections below show what strengthens or weakens the research case.
Score
Reported Results
What the company reported, with filing details kept small.
Quarterly result summary
Revenue was $53M (reported). Operating income was $7.4M (-239% YoY). Net income was $35.7M (-7% YoY).
What changed
- Revenue reported to $53M.
- Operating income -239% YoY to $7.4M.
- Net income -7% YoY to $35.7M.
Guidance / outlook
The Company expects the acquisition to close in the second half of 2026. We have not been informed of any specific issues with our regulatory clearance submission, and based on the information available to us, the timing appears to reflect the ordinary course of the Dutch regulatory review process for a transaction of this nature.
Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.
Other recent earnings materials
Prediction-grade evidence
Recent News
Company-relevant articles from sources that pass the Mave Signal relevance and reliability checks.
Cronos Group Inc (CRON) (Q2 2026) Earnings Call Highlights: Record Revenue and Strategic ...
Headline from Yahoo Finance: Cronos Group Inc (CRON) (Q2 2026) Earnings Call Highlights: Record Revenue and Strategic .
Cronos Group Q2 Earnings Call Highlights
Headline from Yahoo Finance: Cronos Group Q2 Earnings Call Highlights.
Cronos Group Shares Rise After Swing to Q2 Earnings, Higher Revenue
Headline from Yahoo Finance: Cronos Group Shares Rise After Swing to Q2 Earnings, Higher Revenue.
Earnings call transcript: Cronos Group posts Q2 2026 beat, shares jump 13.2%
Headline from Investing.com: Earnings call transcript: Cronos Group posts Q2 2026 beat, shares jump 13.2%.
Cronos Group (CRON) Surpasses Q2 Earnings and Revenue Estimates
Headline from Yahoo Finance: Cronos Group (CRON) Surpasses Q2 Earnings and Revenue Estimates.
Cronos Group Inc. Common Share (CRON) Q2 FY2026 earnings call transcript
Headline from Yahoo Finance: Cronos Group Inc. Common Share (CRON) Q2 FY2026 earnings call transcript.
Earnings Per Share
Return on Equity
ROE
Company —
Sector Median —
ROE
Company —
Sector Median —
ROE
Company —
Sector Median —
ROE
Company —
Sector Median —
Metric chart temporarily unavailable.
Net Margin
Net Margin
Company —
Sector Median —
Net Margin
Company —
Sector Median —
Net Margin
Company —
Sector Median —
Net Margin
Company —
Sector Median —
Metric chart temporarily unavailable.
Leverage
Leverage
Company —
Sector Median —
Leverage
Company —
Sector Median —
Leverage
Company —
Sector Median —
Leverage
Company —
Sector Median —
Metric chart temporarily unavailable.
Financial Statements
Company-reported SEC EDGAR facts organized into the three core statements.
Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.